Drug Shortages: Purchasers Requiring Paybacks; FDA’s Review Policy Questioned
Without a clear regulatory or statutory pathway, FDA’s ability to expedite review of drugs in shortage leaves much to be desired, stakeholders say.
You may also be interested in...
Five-point plan that calls for FDA to change definition of ‘labeling’ and ‘substantial evidence’ may offer hints as to what the next iteration of 21st Century Cures legislation will offer.
Breast cancer meeting highlights challenges of patient-focused drug development as breast cancer patients ask for trials to better identify characteristics of super-responders so patients can make more informed risk-benefit decisions.
NIH official has published articles urging drug development focused on metastasis-prevention.